| | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $1,970,657 ) |
| | 2021 | 2021 | K99HD099307 | Host DNA methylation as a mechanism of microbiome influence on internalizing behavior | 000 | 2 | NIH | 4/12/2021 | 118069611 | $103,415 |
| | 2021 | 2021 | F32CA254286 | Characterizing the effects of cis-regulatory variation on patient outcomes and treatment response in Multiple Myeloma | 002 | 1 | NIH | 2/5/2021 | 118069611 | $3,492 |
| | 2021 | 2021 | F32CA254286 | Characterizing the effects of cis-regulatory variation on patient outcomes and treatment response in Multiple Myeloma | 001 | 1 | NIH | 12/15/2020 | 118069611 | $0 |
| | 2021 | 2021 | F32CA254286 | Characterizing the effects of cis-regulatory variation on patient outcomes and treatment response in Multiple Myeloma | 000 | 1 | NIH | 12/15/2020 | 118069611 | $73,650 |
| | 2021 | 2021 | R01HL145372 | Combining genome, function, and phenotype to define the cell type specific gene regulatory architecture of idiopathic pulmonary fibrosis | 000 | 3 | NIH | 12/31/2020 | 118069611 | $631,134 |
| | 2021 | 2021 | U24AI152172 | A scalable platform for highly-multiplexed analysis of antibody reactivity from <1uL of blood | 001 | 2 | NIH | 4/16/2021 | 118069611 | $337,934 |
| | 2021 | 2021 | U24AI152172 | A scalable platform for highly-multiplexed analysis of antibody reactivity from <1uL of blood | 000 | 2 | NIH | 4/9/2021 | 118069611 | $505,400 |
| | 2021 | 2021 | R21AI149660 | Understanding the natural Coccidioides bioaerosol in time and space and its relationship to disease | 000 | 2 | NIH | 2/5/2021 | 118069611 | $287,269 |
| | 2021 | 2021 | R21AI149311 | A novel approach for deep phenotyping the CD4 T cell response to Mycobacterium Tuberculosis | 000 | 2 | NIH | 1/13/2021 | 118069611 | $280,275 |
| | 2021 | 2020 | UH2CA234306 | Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis | 000 | 1 | NIH | 2/24/2021 | 118069611 | -$251,912 |
| | 2021 | 2020 | UH2AG064706 | Integrative Omics to enhance therapeutics development for healthy aging | 000 | 2 | NIH | 3/30/2021 | 118069611 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $5,485,539 ) |
| | 2020 | 2020 | UH2CA234306 | Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis | 000 | 1 | NIH | 2/20/2020 | 118069611 | $309,491 |
| | 2020 | 2020 | U24AI152172 | A scalable platform for highly-multiplexed analysis of antibody reactivity from <1uL of blood | 000 | 1 | NIH | 4/9/2020 | 118069611 | $505,400 |
| | 2020 | 2020 | U24AI152172 | A scalable platform for highly-multiplexed analysis of antibody reactivity from <1uL of blood | 001 | 1 | NIH | 6/29/2020 | 118069611 | $348,788 |
| | 2020 | 2020 | R21AI149660 | Understanding the natural Coccidioides bioaerosol in time and space and its relationship to disease | 000 | 1 | NIH | 3/13/2020 | 118069611 | $239,767 |
| | 2020 | 2020 | R21AI149311 | A novel approach for deep phenotyping the CD4 T cell response to Mycobacterium Tuberculosis | 000 | 1 | NIH | 2/18/2020 | 118069611 | $255,206 |
| | 2020 | 2020 | U01CA243078 | Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer | 001 | 2 | NIH | 8/25/2020 | 118069611 | $419,136 |
| | 2020 | 2020 | R01CA223481 | Individualized monitoring of treatment response and resistance in patients with metastatic melanoma | 000 | 3 | NIH | 7/21/2020 | 118069611 | $415,333 |
| | 2020 | 2020 | R01DK107735 | Epigenetic markers of severity in nonalcoholic fatty liver disease | 000 | 5 | NIH | 7/29/2020 | 118069611 | $553,850 |
| | 2020 | 2020 | R01HL145372 | Combining genome, function, and phenotype to define the cell type specific gene regulatory architecture of idiopathic pulmonary fibrosis | 000 | 2 | NIH | 12/12/2019 | 118069611 | $665,932 |
| | 2020 | 2020 | R01HL145372 | Combining genome, function, and phenotype to define the cell type specific gene regulatory architecture of idiopathic pulmonary fibrosis | 002 | 2 | NIH | 4/6/2020 | 118069611 | $9,780 |
| | 2020 | 2020 | R01HL145372 | Combining genome, function, and phenotype to define the cell type specific gene regulatory architecture of idiopathic pulmonary fibrosis | 001 | 2 | NIH | 3/13/2020 | 118069611 | $35,049 |
| | 2020 | 2020 | UH2AG064706 | Integrative Omics to enhance therapeutics development for healthy aging | 001 | 2 | NIH | 9/9/2020 | 118069611 | $173,002 |
| | 2020 | 2020 | UH2AG064706 | Integrative Omics to enhance therapeutics development for healthy aging | 000 | 2 | NIH | 8/27/2020 | 118069611 | $603,297 |
| | 2020 | 2020 | K99CA234391 | Characterization of the role of super-enhancers in ovarian cancer treatment response | 001 | 2 | NIH | 8/12/2020 | 118069611 | $54,000 |
| | 2020 | 2020 | K99CA234391 | Characterization of the role of super-enhancers in ovarian cancer treatment response | 000 | 2 | NIH | 7/27/2020 | 118069611 | $84,428 |
| | 2020 | 2020 | R01DK120890 | Profiling extracellular vesicle cargo in obesity and type 2 diabetes | 001 | 2 | NIH | 8/10/2020 | 118069611 | $722,401 |
| | 2020 | 2020 | K99HD099307 | Host DNA methylation as a mechanism of microbiome influence on internalizing behavior | 000 | 1 | NIH | 4/6/2020 | 118069611 | $90,680 |
| | 2020 | 2019 | U01CA243078 | Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer | 000 | 1 | NIH | 3/12/2020 | 118069611 | $0 |
| | 2020 | 2019 | R01DK120890 | Profiling extracellular vesicle cargo in obesity and type 2 diabetes | 000 | 1 | NIH | 11/8/2019 | 118069611 | $0 |
| | 2020 | 2017 | R01AG048907 | CATT: Development and Application of a Neuronal Cell Activity-Tagging Toolbox | 000 | 4 | NIH | 4/11/2020 | 118069611 | $0 |
| | 2020 | 2017 | UH3TR000891 | exRNA signatures Predict Outcomes after brain injury | 000 | 5 | NIH | 2/1/2020 | 118069611 | -$1 |
|
| Issue Date FY: 2019 ( Subtotal = $3,825,900 ) |
| | 2019 | 2019 | R01DK107735 | Epigenetic markers of severity in nonalcoholic fatty liver disease | 001 | 4 | NIH | 7/30/2019 | 118069611 | $597,446 |
| | 2019 | 2019 | R01HL145372 | Combining genome, function, and phenotype to define the cell type specific gene regulatory architecture of idiopathic pulmonary fibrosis | 000 | 1 | NIH | 12/24/2018 | 118069611 | $753,281 |
| | 2019 | 2019 | R01DK120890 | Profiling extracellular vesicle cargo in obesity and type 2 diabetes | 000 | 1 | NIH | 9/16/2019 | 118069611 | $712,558 |
| | 2019 | 2019 | K99CA234391 | Characterization of the role of super-enhancers in ovarian cancer treatment response | 000 | 1 | NIH | 7/30/2019 | 118069611 | $84,428 |
| | 2019 | 2019 | R01CA223481 | Individualized monitoring of treatment response and resistance in patients with metastatic melanoma | 001 | 2 | NIH | 7/25/2019 | 118069611 | $402,872 |
| | 2019 | 2019 | R01DK107735 | Epigenetic markers of severity in nonalcoholic fatty liver disease | 001 | 4 | NIH | 7/30/2019 | 118069611 | $118,104 |
| | 2019 | 2019 | R01DK107735 | Epigenetic markers of severity in nonalcoholic fatty liver disease | 000 | 3 | NIH | 5/27/2019 | 118069611 | $118,104 |
| | 2019 | 2019 | U01CA243078 | Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer | 000 | 1 | NIH | 9/18/2019 | 118069611 | $440,008 |
| | 2019 | 2019 | UH2AG064706 | Integrative Omics to enhance therapeutics development for healthy aging | 000 | 1 | NIH | 9/12/2019 | 118069611 | $599,100 |
| | 2019 | 2018 | R01CA223481 | Individualized monitoring of treatment response and resistance in patients with metastatic melanoma | 000 | 1 | NIH | 7/24/2019 | 118069611 | $0 |
| | 2019 | 2017 | R01CA169281 | Targeting Stromal Collagen in Pancreatic Cancer | 000 | 5 | NIH | 7/30/2019 | 118069611 | $0 |
| | 2019 | 2016 | U01CA168397 | Systematic Development of Novel, Druggable Cancer Targets | 000 | 5 | NIH | 11/5/2018 | 118069611 | -$1 |
| | 2019 | 2016 | R01AI101371 | Rapid Emergence of Livestock-associated MRSA ST398: Host-adaptation & Virulence | 000 | 4 | NIH | 11/2/2018 | 118069611 | $0 |
| | 2019 | 2016 | R21NS093222 | Identification of pathogenic mechanisms important in multiple system atrophy | 000 | 2 | NIH | 2/18/2019 | 118069611 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,761,115 ) (Continued on the next page) |
|
